Three AHSNs (Oxford, Yorkshire & Humber and Health Innovation Manchester) have made it through to the finals of this year’s HSJ Partnership Awards, recognising the most effective partnerships between the private and third sector and the NHS.
HSJ editor Alastair McLellan said: “The HSJ Partnership Awards highlights the invaluable work performed by the organisations that work alongside the NHS to deliver first class patient care, shining a spotlight on their efforts which are often unseen but are essential. Each of the shortlisted organisations is delivering tangible benefits to NHS patients, clinicians and the facilities they use, making a real difference in these challenging economic times.”
The awards will be presented on 20 March in at the Westminster Park Plaza in London.
The AHSNs have been shortlisted in the following categories:
Best Pharmaceutical Partnership with the NHS
- Excellence in AF – Bayer, Oxford AHSN and Buckinghamshire CCG
- UK first memorandum of understanding between the NHS and pharmaceutical industry – Health Innovation Manchester and ABPI
Best Healthcare Provider Partnership
- Changing Clinical Practice – Roche Diagnostics and Oxford AHSN
Medical Device or Hardware Innovation Award
- #ALifeMoreNormal – Tookie and Yorkshire & Humber AHSN
Patient Digital Participation Award
- Digital patient letters transforming hospital communications – Yorkshire & Humber AHSN, Healthcare Communications & Barnsley Hospial Foundation Trust
Workforce Innovation Award
- Improving workforce capacity and patient outcomes in urgent care through digital innovation – Doc Abode, Local Care Direct and Yorkshire and Humber AHSN
Excellence in AF
Speaking about the ‘Excellence in AF’ initiative being shortlisted, Oxford AHSN Chief Executive and the AHSN Network’s national atrial fibrillation lead, Professor Gary Ford, said: “We are delighted that the success of this work to reduce stroke has been recognised.
“It has brought together expertise from primary care, industry and the AHSN to identify people with atrial fibrillation at risk of having a stroke and optimise their care so they are less likely to have one. This has been shown to improve lives to both prevent disability and reduce NHS costs.”
Workforce innovation and patient digital participation
Sophie Bates, Programme Manager for the Yorkshire & Humber AHSN said: ‘’It is great to see that Tookie, Healthcare Communications and Doc Abode have been recognised for their contribution to healthcare innovation by being shortlisted for the HSJ Partnership Awards. Each has a unique offer with the potential to contribute to patient safety, to the patient experience, and to increased efficiencies within the NHS.” Read more about these shortlisted projects here.
UK first memorandum of understanding between the NHS and pharmaceutical industry
In February 2017 Health Innovation Manchester and the Association of British Pharmaceutical Industry (ABPI) signed a landmark Memorandum of Understanding (MoU) to transform access to medicines for patients in Greater Manchester. Empowered by devolution, this unique partnership has gone from strength to strength. The creation of the Greater Manchester and Pharmaceutical Industry Partnership Group enabled by the MoU has profoundly impacted on the regions relationship with industry, delivering direct benefits to patients, the healthcare system, academia and the local economy.
Mike Thompson, Chief Executive of the ABPI said: “Thanks to the vision, collaborative spirit and patient focus of its health and social care leaders, Manchester is becoming a magnet for industry investment and is now internationally recognised as a key UK life sciences asset. The ABPI is immensely proud to have played a part in this achievement. We look forward to the next phase of collaboration with our partners at Health Innovation Manchester to help deliver a digital innovation strategy that benefits patients, citizens, the NHS and industry.”
Changing clinical practice
Through its Maternity Network, the Oxford AHSN is supporting the implementation of the Elecsys sFlt-1:PlGF test, developed by Roche Diagnostics, as a patient safety initiative to rule out pregnant women who do not have, and have a low chance of developing, pre-eclampsia – a multi-system hypertensive disorder of pregnancy.
Chris Hudson, Director of Healthcare Development and Strategic Services at Roche Diagnostics, commented: “Despite receiving NICE guidance recommendation in May 2016, the uptake of the sFlt/PlGF pre-eclampsia ratio test has been slow. Working in partnership with the Oxford AHSN meant the right stakeholders were brought together with a clear plan developed to accelerate the adoption of this innovation. The AHSN was committed from day one to lead on this project with a dedicated point of contact managing communication across all stakeholders. This collaboration has resulted in patients successfully getting access to this innovation in their region.”